Vertex Pharmaceuticals (NASDAQ:VRTX)‘s stock had its “buy” rating restated by Citigroup in a research note issued on Thursday, Briefing.com Automated Import reports. They currently have a $205.00 target price on the pharmaceutical company’s stock. Citigroup‘s price target points to a potential upside of 19.92% from the company’s previous close.

VRTX has been the subject of several other research reports. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $209.00 price target on shares of Vertex Pharmaceuticals in a research note on Wednesday, May 1st. ValuEngine raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Svb Leerink reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, March 19th. BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, Cowen reaffirmed a “buy” rating and set a $220.00 price target on shares of Vertex Pharmaceuticals in a research note on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and seventeen have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $204.36.

VRTX stock traded down $1.42 during mid-day trading on Thursday, hitting $170.95. 291,761 shares of the company were exchanged, compared to its average volume of 1,055,115. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.66. The firm has a market cap of $43.32 billion, a PE ratio of 60.41, a price-to-earnings-growth ratio of 2.45 and a beta of 1.56. Vertex Pharmaceuticals has a 12-month low of $144.07 and a 12-month high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.49. The company had revenue of $857.00 million during the quarter, compared to analyst estimates of $853.00 million. Vertex Pharmaceuticals had a net margin of 66.01% and a return on equity of 22.63%. Vertex Pharmaceuticals’s revenue was up 34.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.76 earnings per share. Sell-side analysts anticipate that Vertex Pharmaceuticals will post 3.06 EPS for the current fiscal year.

In other news, SVP Paul M. Silva sold 161 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $165.41, for a total transaction of $26,631.01. Following the completion of the transaction, the senior vice president now owns 17,759 shares of the company’s stock, valued at approximately $2,937,516.19. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CMO Reshma Kewalramani sold 241 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $165.41, for a total transaction of $39,863.81. Following the transaction, the chief marketing officer now directly owns 13,736 shares of the company’s stock, valued at approximately $2,272,071.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 51,247 shares of company stock valued at $8,998,147. Corporate insiders own 0.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of VRTX. RMB Capital Management LLC grew its stake in shares of Vertex Pharmaceuticals by 3.0% in the fourth quarter. RMB Capital Management LLC now owns 21,113 shares of the pharmaceutical company’s stock worth $3,499,000 after purchasing an additional 617 shares in the last quarter. State Treasurer State of Michigan raised its stake in shares of Vertex Pharmaceuticals by 74.8% during the fourth quarter. State Treasurer State of Michigan now owns 133,168 shares of the pharmaceutical company’s stock valued at $22,067,000 after acquiring an additional 57,000 shares during the last quarter. HighPoint Advisor Group LLC raised its stake in shares of Vertex Pharmaceuticals by 3.2% during the fourth quarter. HighPoint Advisor Group LLC now owns 5,097 shares of the pharmaceutical company’s stock valued at $952,000 after acquiring an additional 160 shares during the last quarter. Biondo Investment Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 8.8% during the fourth quarter. Biondo Investment Advisors LLC now owns 46,020 shares of the pharmaceutical company’s stock valued at $7,626,000 after acquiring an additional 3,715 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in Vertex Pharmaceuticals by 25.6% in the fourth quarter. Canada Pension Plan Investment Board now owns 432,373 shares of the pharmaceutical company’s stock worth $71,643,000 after buying an additional 88,000 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Read More: Are FAANG stocks a good investment?

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.